Arthrosi Therapeutics

Arthrosi Therapeutics, Inc. is a late-stage clinical biotechnology company founded in 2018 and headquartered in San Diego, California, by a team of gout specialists who previously led first-generation urate-transporter development at Ardea Biosciences. Its lead candidate, pozdeutinurad (AR882), is a once-daily oral next-generation URAT1 inhibitor in two fully enrolled replicate global Phase 3 trials (REDUCE 1 and REDUCE 2) for progressive and tophaceous gout, backed by roughly $299M in venture financing including a $153M Series E led by Prime Eight Capital. Sobi (Swedish Orphan Biovitrum) completed its acquisition of Arthrosi on 9 February 2026. Arthrosi is a drug developer, not a software company: it operates a WordPress corporate site with company, leadership and news pages, and publishes no developer portal, public API, SDK, package or machine-readable specification of any kind.

Arthrosi Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Clinical Trials.

Arthrosi Therapeutics’ developer surface includes engineering blog and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub

7.0/100 minimal ▬ flat Agent 4/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsLife SciencesClinical TrialsDrug DevelopmentGoutRheumatologyHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 7.0/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 5.5 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 4/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 4 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/arthrosi-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 4

The organization behind the API

Website

Website

About

About

Blog

Blog

LinkedIn

Other 2

Properties that don't map to a standard resource type

Team

Team

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: arthrosi-therapeutics
name: Arthrosi Therapeutics
description: 'Arthrosi Therapeutics, Inc. is a late-stage clinical biotechnology company founded in 2018 and headquartered
  in San Diego, California, by a team of gout specialists who previously led first-generation urate-transporter development
  at Ardea Biosciences. Its lead candidate, pozdeutinurad (AR882), is a once-daily oral next-generation URAT1 inhibitor in
  two fully enrolled replicate global Phase 3 trials (REDUCE 1 and REDUCE 2) for progressive and tophaceous gout, backed by
  roughly $299M in venture financing including a $153M Series E led by Prime Eight Capital. Sobi (Swedish Orphan Biovitrum)
  completed its acquisition of Arthrosi on 9 February 2026. Arthrosi is a drug developer, not a software company: it operates
  a WordPress corporate site with company, leadership and news pages, and publishes no developer portal, public API, SDK,
  package or machine-readable specification of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/arthrosi-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Clinical Trials
- Drug Development
- Gout
- Rheumatology
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/arthrosi-therapeutics-domain-security.yml
- type: Website
  url: https://arthrosi.com/
- type: About
  url: https://arthrosi.com/company/
- type: Team
  url: https://arthrosi.com/team/
- type: Blog
  url: https://arthrosi.com/news-media/
- type: LinkedIn
  url: https://www.linkedin.com/company/arthrosi-therapeutics-inc
- type: SecondaryMarket
  url: https://forgeglobal.com/arthrosi-therapeutics_stock/
- type: LLMsTxt
  url: llms/arthrosi-therapeutics-llms.txt
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Arthrosi is a San Diego drug developer whose product is a Phase 3 oral gout molecule (pozdeutinurad/AR882, acquired
    by Sobi in February 2026), not software — there is no GitHub org, no package on any registry and no api/docs/developer
    subdomain in DNS, and its single web property is a WordPress marketing site that answers HTTP 202 with a SiteGround sgcaptcha
    interstitial to every path including /robots.txt and a bogus control path, so even the marketing copy is machine-unreadable.
  evidence:
  - url: https://arthrosi.com/robots.txt
    status: 202
  - url: https://arthrosi.com/.well-known/agent-card.json
    status: 202
  - url: https://api.github.com/orgs/arthrosi
    status: 404
  - url: https://pypi.org/pypi/arthrosi/json
    status: 404
  checked: '2026-08-06'